Pharmacology and Drug Discovery in the Allosteric World DVD
About the DVD:
The advancing technology of high-throughput screening is changing the type of molecules found. With protein function more physiologically relevant, the quality of the molecules that pharmacologists and medicinal chemists must deal with is changing. This course will familiarize researchers with the tools needed to exploit this potentially fruitful area of new drug discovery through discussion of allosteric molecules, detection of allosterism, and quantifying allosterism for chemical lead optimization. The course is designed to answer these questions:
What is protein allostery?
What makes allosteric molecules unique and how can this contribute to unique therapeutic properties?
How can we detect allosterism?
How to quantify allosterism for chemical lead optimization?
About Discovery On Target:
Discovery on Target is known as the leading event showcasing novel "hot" targets for the pharmaceutical industry will be held November 2-4 in Boston, Massachusetts at the historic Park Plaza Hotel & Towers.
This is a must attend event to keep up with current and upcoming developments in target discovery and to collaborate and connect with experienced scientists and high level decision makers.
Networking opportunities will be available through interactive sessions including roundtable breakouts, workshops and panel discussions.
Create your own agenda by moving between the conference programs and choose the sessions that best fit your research and networking needs.
About the DVD:
Over 113 Minutes
Site License: $1380
Conference At A Glance:
Terry P. Kenakin, Ph.D., Professor, Department of Pharmacology, University of North Carolina School of Medicine
Terry Kenakin is Research Professor in the Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina. Terry obtained his B.S. in chemistry and Ph.D. in Pharmacology at the University of Alberta, Canada. After 3 years at University College, London, UK, he joined Burroughs-Wellcome as a Senior Research Pharmacologist. Terry then went on to join Glaxo, which became Glaxo-Wellcome and subsequently GlaxoSmithKline, where his work involved the use of quantitative receptor pharmacology and theory to advance new drug discovery programs. He applies quantitative pharmacologic concepts to drug dose-response data to provide medicinal chemists with scales to optimize drug activity. He has written 9 books on Pharmacology and is co-Editor-in-Chief of the Journal of Receptors and Signal Transduction and also Current Opinion in Pharmacology. His current interests center on the therapeutic exploitation of the 7TM receptor functional selectivity and allosteric control of the 7TM receptor signaling.
Annette Gilchrist, Ph.D., Assistant Professor, Pharmaceutical Sciences, Midwestern University
Annette Gilchrist received her M.S. in Biochemistry from the University of Connecticut and Ph.D. in Immunology from the University of Connecticut Health Center. Following a postdoctoral fellowship with Dr. Heidi Hamm, Dr. Gilchrist went on to cofound Caden Biosciences and Cue BIOtech, companies committed to GPCR drug discovery efforts. Currently, Dr. Gilchrist is an Assistant Professor in the Department of Pharmaceutical Sciences at Midwestern University’s Chicago of Pharmacy, and an Adjunct Professor at Northwestern University in the Department of Molecular Pharmacology and Biological Chemistry. Her work is focused on functional selectivity and allosteric regulation of GPCRs. Dr. Gilchrist has twenty-five peer-reviewed publications and four issued patents including a just publishedmanuscript that was cited as a "must read" by the Faculty of 1000. In addition, she recently served as editor for a book by Wiley entitled GPCR Molecular Pharmacology and Drug Targeting: Shifting Paradigms and New Directions